4 January 2016 - According to the findings, no added benefit is proven for trametinib monotherapy because of a lack of suitable study data. For the combination therapy, however, there is an indication of a major added benefit for women and of a non-quantifiable added benefit for men.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/dabrafenib/trametinib-in-advanced-melanoma-with-braf-v600-mutation-indication-of-added-benefit.7122.html